NCT00041665View on ClinicalTrials.gov

Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Stomatitis
Interventions
DRUG

Recombinant Human Keratinocyte Growth Factor

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00041665 - Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy | Biotech Hunter | Biotech Hunter